Recursion (RXRX) Climbs 12.09% on May 13

Equities Staff  |

Shares of Recursion Pharmaceuticals Inc - Class A (NASDAQ: RXRX) moved 12.09% Friday.

As of 12:08:02 est, Recursion is currently sitting at $5.83 and has risen $0.63 so far today.

Recursion has moved 27.64% over the last 30 days and has a YTD change of 69.59% based on the prior day’s close.

The company expects its next earnings on 2022-08-12.

For technical charts, analysis, and more on Recursion visit the company profile.

About Recursion Pharmaceuticals Inc - Class A

Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Central to its mission is the Recursion Operating System, or Recursion OS, that combines an advanced infrastructure layer to generate what Recursion believes is one of the world's largest and fastest-growing proprietary biological and chemical datasets and the Recursion Map, a suite of custom software, algorithms, and machine learning tools that the company uses to explore foundational biology unconstrained by human bias and navigate to new biological insights which may accelerate its programs. biotechnology company scaling more like a technology company.

To get more information on Recursion Pharmaceuticals Inc - Class A and to follow the company's latest updates, you can visit the company's profile page here: Recursion Pharmaceuticals Inc - Class A's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Twitter Down 13% in Premarket Trading Friday as Musk Puts Deal on Hold
The Best Laid Plans of Mice and Men — Part I
Bumble Beats First Quarter Estimates, Has Over 3 Million Paying Users
Squarespace Beats Revenue Estimates With Record Q1
BridgeBio Pharma Inks Licensing Deal With Bristol Myers Squibb Worth up to $905 Million
How To Trade in a Bearish Market
AbbVie and Teva Weighing $5 Billion Opioid Lawsuit Settlement



Market Movers

Sponsored Financial Content